Clear All
744 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
S2107 Immunotherapy - non specific Adoptive immunotherapy (ie development of specific anti-tumor reactivity) NA Immunotherapy No Apr 1, 2002 In Use
J9217 Leuprolide Acetate Eligard, Lupron Depot, Viadur, Lupron 7.5 mg Hormonal Therapy GnRH Agonist No 1989 Jan 1, 1997 In Use
NA Cyclosporine NeOral 25mg, 100mg Ancillary Therapy Immunomodulator Calcineurin Inhibitor Yes 1995 In Use
NA Dasatinib Sprycel 70 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
J8501 Aprepitant Emend 5 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 Jan 1, 2005 In Use
J0641 Levoleucovorin Fusilev, Levoleucovorin 0.5 mg Ancillary Therapy Chemoprotective Antidote No 2008 Oct 1, 2019 In Use
J9219 Leuprolide Acetate Implant Viadur 65 mg Hormonal Therapy GnRH Agonist No 2000 Jan 1, 2016 In Use
NA Pomalidomide Pomalyst 3 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2013 In Use
NA Dabrafenib Tafinlar 50 mg Chemotherapy Tyrosine Kinase Inhibitor BRAF Yes 2013 Jan 1, 2004 In Use
NA Nilotinib Tasigna 150 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
J9299 Nivolumab Opdivo 1 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2014 Jan 1, 2016 In Use
J9025 Azacitidine Vidaza 1 mg Chemotherapy Antimetabolite Pyrimidine Analog No 2004 Jan 1, 2006 In Use
J3590 Immunotherapy - non specific Unclassified biologics NA Immunotherapy No Jan 1, 2003 In Use
J9216 Interferon Gamma-1b Actimmune 3 million units Immunotherapy Cytokine Interferon No 1999 Jan 1, 2009 In Use
NA Nintedanib Ofev 100 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, FLT3 Yes 2014 In Use
J2783 Rasburicase Elitek, Fasturtec 0.5 mg Ancillary Therapy Metabolic Agent Enzyme No 2002 Jan 1, 2004 In Use
J9051 Bortezomib (Maia) Bortezomib 0.1mg Chemotherapy Proteasome Inhibitor 26S Yes 2022 Aug 28, 2023 In Use
NA Crizotinib Xalkori 250 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2011 In Use
J8530 Cyclophosphamide Cyclophosphamide oral 25 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1959 Jan 1, 1995 In Use
NA Lapatinib Tykerb 250 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2007 In Use
NA Lenalidomide Revlimid 5 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2005 In Use
J2650 Prednisolone Acetate Flo-Pred [DSC], Millipred, Millipred DP, Orapred ODT, Orapred [DSC], Pediapred, Prednisone Intensol, Veripred 20, Prednisolone Sodium Phosphate 1 ml Hormonal Therapy Adrenal Glucocorticoid Corticosteroid No 1955 Jan 1, 1997 In Use
J9262 Omacetaxine Synribo 0.01 mg Chemotherapy Plant Alkaloid BCR-ABL No 2012 Jan 1, 2014 In Use
NA Vandetanib Caprelsa 300 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
J9092 Cyclophosphamide Cyclophosphamide 2 g Chemotherapy Alkylating Agent Nitrogen Mustard No 1959 Jan 1, 1994 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.